Jacob Gottlieb, MD, CFA, PRMIA is a very successful entrepreneur who searches for enterprises with health and medical treatment advances. He founded Visium Asset Management before Altium Capital in 2005. Altium Capital, whose home base is located in New York City, is next on his list. Oramed Pharmaceuticals (ORMP), Amarin Corporation (AMRN) and Oragenics are some of the investments of Altium Capital. Oramed Pharmaceuticals created an oral treatment for patients with diabetes who are receiving the injectable drugs and has proven to be successful. Altium Capital has invested in this company first with a 5.61% stake.
Amarin Corporation is growing rapidly and is headquartered in Dublin, Ireland and also has offices located in Bedminster, New Jersey. They specialize in creating drugs to improve cardiovascular health. Vascepa, which is the first FDA-approved drug by Amarin, and its other drugs is a combination between science and the benefits of fatty acids.
Oragenics was founded by two physicians in 1996 with the concept of Replacement Therapy. Replacement Therapy is the process where the bad bacteria is replaced with the good bacteria in order for the body to create its own antibiotics to fight and ward off diseases and any illnesses. This process is quite effective and is used quite often today.
Gottlieb was a founding member at Balyasny Asset Management, L.P. (BAM) before he founded Visium Asset Management, LLC and was known for his large portfolio gains and being a top earner. His Education ranges with a BA in Economics from Brown University. He also holds an MD from New York University Medical School. Right after he had an internal medicine internship. His strong interest in investing is what led him to where he is today. In 2001, he received his Chartered Financial Analyst (CFA) charter and his P.R.M. designation in 2010.